Smart-phone Application to Promote Medication Adherence in Adolescents and Young Adults (AYA) With Cancer
Use of a Smart-phone Medication Reminder Application to Promote Adherence to Oral Medications by Adolescents and Young Adults(AYA) With Cancer
1 other identifier
observational
32
1 country
1
Brief Summary
To explore use of a smart-phone medication reminder application to promote adherence to oral medications by AYA with cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 25, 2012
CompletedStudy Start
First participant enrolled
May 1, 2012
CompletedFirst Posted
Study publicly available on registry
June 13, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2017
CompletedResults Posted
Study results publicly available
November 6, 2017
CompletedNovember 6, 2017
October 1, 2017
4.6 years
April 25, 2012
September 8, 2017
October 5, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Feasibility and Acceptability of Using a Smart-phone Medication Reminder Application to Promote Adherence to Oral Medications by AYA With Cancer.
Feasibility was assessed through participants' application usage and responses to self-reported questions about their use of the application. Acceptability was assessed through participants' perceived ease of use and perceived usefulness of the application.
ongoing study weeks 5-12
Eligibility Criteria
Primary care clinics for patients be treated for cancer.
You may qualify if:
- )15-29 year olds receiving treatment for any type of cancer, either primary or recurrent/relapsed disease.
- \) Patient has completed at least one month of therapy
- )Patient is expected to remain on therapy for 3 month duration of study
- \) Patient has an iPhone, iPad, or iTouch running iOS 4.0 or later
- \) Patient is willing to use a smart-phone medication reminder application-
You may not qualify if:
- )Patients who are unable to speak/read/write English as required for use of smart-phone medication reminder application and completion of study measures.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Utahlead
- Oncology Nursing Societycollaborator
Study Sites (1)
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
Small pilot trial (single group). Pre-post measurements only.
Results Point of Contact
- Title
- Dr. Yelena Wu
- Organization
- Hunstman Cancer Institute
Study Officials
- PRINCIPAL INVESTIGATOR
Yelena Wu, PhD
Huntsman Cancer Institute
- PRINCIPAL INVESTIGATOR
Lauri Linder, PhD
University of Utah
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
April 25, 2012
First Posted
June 13, 2012
Study Start
May 1, 2012
Primary Completion
December 1, 2016
Study Completion
February 1, 2017
Last Updated
November 6, 2017
Results First Posted
November 6, 2017
Record last verified: 2017-10